Protagonist Therapeutics (PTGX) stock is experiencing a significant surge in the market, soaring 5.11% during Monday's intraday trading session. This impressive rally comes on the heels of two major Wall Street firms raising their price targets for the biopharmaceutical company.

Goldman Sachs has substantially increased its price target for Protagonist Therapeutics from $47 to $65, while maintaining a Neutral rating on the shares. This represents a notable 38% increase in their valuation of the company. In a similar move, Citigroup has also raised its target price for PTGX, albeit more modestly, from $96 to $98.

These upward revisions in price targets from prominent financial institutions often signal increased confidence in a company's future prospects. For investors, such analyst upgrades can serve as a catalyst for buying activity, potentially explaining the sharp increase in Protagonist Therapeutics' stock price. As the market digests this positive sentiment from Wall Street analysts, it appears that traders and investors are repositioning themselves, driving the stock's value higher.